Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma

Lale Kostakoglu, MD MPH, Andrew Davies, MD PhD, Michael Herold, Wolfgang Hiddemann, Robert Marcus, Judith Trotman, FRACP, Andrea Knapp, Federico Mattiello, Tina G Nielsen, Deniz Sahin, Carol Ward, Anas Younes

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-134784

Published: 2020

Journal Articles

Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study

Carsten Henneges, Dexter X Jin, Jeffrey M Venstrom, Sally E Trabucco, PhD, Tina G Nielsen, Elicia M. Penuel, Sarah Huet, Gilles Salles, MD PhD, Joseph N Paulson

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-134795

Published: 2020

Journal Articles

Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients

Skander Jemaa, Samuel Tracy, Alessia Bottos, Alex de Crespigny, Thomas Bengtsson, Tina G Nielsen, Joseph N Paulson

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-134780

Published: 2020

Journal Articles

A Prognostic Model Incorporating Tumor Lesion Morphology and Texture Features Identifies High-Risk Patient Subpopulations in De Novo DLBCL and FL

Xiao Li, Skander Jemaa, Richard AD Carano, Thomas Bengtsson, Joseph N Paulson, Gunther Jansen, Tina G Nielsen, Derrek P Hibar

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-134877

Published: 2020

Journal Articles

Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma

Mark Yan, Yi Meng Chang, Vibha Raghavan, Estella Dong, Christian Klein, PhD, Tina G Nielsen, Joseph N Paulson, Katerina Hatzi

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-134867

Published: 2020

Journal Articles

The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136544

Published: 2020

Journal Articles

TRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making

Edward Bataillard, Will Harris, Tarec Christoffer El-Galaly, Antonia Kwan, Carsten Henneges, Joseph N Paulson, Tina G Nielsen

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134904

Published: 2020

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 2874.

https://doi.org/10.1182/blood-2019-123368

Published: 2019

Journal Articles

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Blood (2019) 134 (Supplement_1): 2812.

https://doi.org/10.1182/blood-2019-122328

Published: 2019

Journal Articles

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Laurie H Sehn, MD, Marek Trněný, MD, Kamal Bouabdallah, MD, Gregory Dueck, MD, John G. Gribben, MD DSc, P.J. Lugtenburg, MD PhD, Gilles A. Salles, MD PhD, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Wenxin Liu, PhD, Bruce D. Cheson, MD

Blood (2019) 134 (Supplement_1): 2822.

https://doi.org/10.1182/blood-2019-123422

Published: 2019

Journal Articles

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Eugene C Kim, PhD, Jinzhen Fan, PhD, Christopher R Bolen, PhD, Alexandra Bazeos, MD PhD FRCPath, Yanwen Jiang, PhD, Sandhya Balasubramanian, MS, Rama Balakrishnan, PhD, Andrea Knapp, PhD, Kathryn Humphrey, BSc, Tina G Nielsen, MD PhD, Jeffrey M. Venstrom, MD PhD, Genevive Hernandez, PhD, Joseph N Paulson, PhD

Blood (2019) 134 (Supplement_1): 2788.

https://doi.org/10.1182/blood-2019-124687

Published: 2019

Journal Articles

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Lale Kostakoglu, MD MPH, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Andrea Knapp, PhD, Federico Mattiello, PhD, Tina G Nielsen, MD PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Carol Ward, MSc, Anas Younes, MD

Blood (2019) 134 (Supplement_1): 489.

https://doi.org/10.1182/blood-2019-123626

Published: 2019

Journal Articles

Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma

Ehsan Tabari, PhD, Alexander F Lovejoy, PhD, Hai Lin, PhD, Christopher R Bolen, PhD, Seng Lor Saelee, BA, Joshua P Lefkowitz, David M. Kurtz, MD PhD, Patrik Vitazka, MD PhD, Jeffrey M. Venstrom, MD PhD, Tina G Nielsen, MD PhD, Joana M Parreira, MD, Daniel M Klass, PhD, Khai T Luong, PhD

Blood (2019) 134 (Supplement_1): 490.

https://doi.org/10.1182/blood-2019-123633

Published: 2019

Journal Articles

A Fully Automated Measurement of Total Metabolic Tumor Burden in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Skander Jemaa, MS, Jill Fredrickson, PhD, Alexandre Coimbra, PhD, Richard AD Carano, PhD, Tarec Christoffer C. El-Galaly, MD, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Deniz Sahin, BSc, Thomas Bengtsson, PhD, Alex de Crespigny, PhD

Blood (2019) 134 (Supplement_1): 4666.

https://doi.org/10.1182/blood-2019-124793

Published: 2019

Journal Articles

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Donald Berry, PhD, Kristine Broglio, MS, Carol Ward, MSc, Federico Mattiello, PhD, Deniz Sahin, BSc, Tina G Nielsen, MD PhD, Anna McGlothlin, PhD, Corrine Elliott, MS, Thomas E. Witzig, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Maurizio Martelli, MD, Lale Kostakoglu, MD MPH, Grzegorz Nowakowski, MD

Blood (2019) 134 (Supplement_1): 4101.

https://doi.org/10.1182/blood-2019-124067

Published: 2019

Journal Articles

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Carla Casulo, Michael Herold, MD, Wolfgang Hiddemann, MD PhD, Sunil Iyengar, MD, Robert E. Marcus, FRCP, John F. Seymour, MBBS, PhD FRACP, Aino Launonen, MSc, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Farheen Mir, MBBS, MD

Blood (2019) 134 (Supplement_1): 5268.

https://doi.org/10.1182/blood-2019-123466

Published: 2019

Journal Articles

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Lale Kostakoglu, MD MPH, Paola Berchialla, PhD, Federico Dalmasso, PhD, Larry A Pierce, PhD, Umberto Vitolo, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Tina G Nielsen, MD PhD, Christopher R Bolen, PhD, Deniz Sahin, BSc, Calvin Lee, MD, Tarec Christoffer C. El-Galaly, MD, Federico Mattiello, PhD, Paul E Kinahan, PhD, Stephane Chauvie, PhD

Blood (2019) 134 (Supplement_1): 883.

https://doi.org/10.1182/blood-2019-123450

Published: 2019

Journal Articles

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

William G. Wierda, Thomas J. Kipps, Jan Dürig, Laimonas Griskevicius, Stephan Stilgenbauer, Jiří Mayer, Lukáš Smolej, Georg Hess, Rasa Griniute, Francisco J. Hernandez-Ilizaliturri, Swaminathan Padmanabhan, Michele Gorczyca, Chai-Ni Chang, Geoffrey Chan, Ira Gupta, Tina G. Nielsen, Charlotte A. Russell

Blood (2011) 117 (24): 6450–6458.

https://doi.org/10.1182/blood-2010-12-323980

Published: 2011

Includes: Supplemental data

Journal Articles

Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.

William G Wierda, Thomas J Kipps, Jan Dürig, Laimonas Griskevicius, Stephan Stilgenbauer, Jiri Mayer, Lukas Smolej, Georg Hess, Rasa Griniute, Francisco J Hernandez-Ilizaliturri, Swaminathan Padmanabhan, Michele Gorczyca, Geoffrey Chan, Ira Gupta, Marc Andersen, Claus Strange, Tina G Nielsen, Charlotte A Russell

Blood (2009) 114 (22): 207.

https://doi.org/10.1182/blood.V114.22.207.207

Published: 2009

NARROW

Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma

Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study

Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients

A Prognostic Model Incorporating Tumor Lesion Morphology and Texture Features Identifies High-Risk Patient Subpopulations in De Novo DLBCL and FL

Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma

The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World

TRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma

A Fully Automated Measurement of Total Metabolic Tumor Burden in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only